Results 41 to 50 of about 16,901 (99)

Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters

EJNMMI Radiopharmacy and Chemistry
Background Lutetium-177 (177Lu) theranostics have revolutionized personalized cancer treatment, particularly with FDA-approved therapies like [177Lu]Lu-DOTA-TATE for neuroendocrine tumors and [177Lu]Lu-PSMA for prostate cancer.
William Hunt, Mathew Long, Usama Kamil, Sunil Kellapatha, Wayne Noonan, Peter D. Roselt, Nathan Papa, Brittany Emmerson, Michael S. Hofman, Mohammad B. Haskali   +9 more
doaj   +1 more source

Radiopharmacologist’s and Radiochemist’s View on Targeting the Eph/Ephrin Receptor Tyrosine Kinase System

ACS Omega, 2020
Christin Neuber, Birgit Belter, Constantin Mamat, Jens Pietzsch   +3 more
doaj   +1 more source

Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM

International Journal of Translational Medicine
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity ...
Tihomir Zh. Todorov, Roger Schibli, Martin Béhé, Jürgen Grünberg   +3 more
doaj   +1 more source

Hydrogel-Based Strategies for the Prevention and Treatment of Radiation-Induced Skin Injury: Progress and Mechanistic Insights

Biomimetics
Radiation-induced skin injury (RISI) is one of the most common complications of radiotherapy, severely compromising patients’ quality of life. However, no standardized treatment has yet been established.
Yinhui Wang, Huan Liu, Yushan He, Mei Li, Jie Gao, Zongtai Han, Jiayu Zhou, Jianguo Li   +7 more
doaj   +1 more source

Optimized production of 89Zr as a medical radioisotope on a variable energy cyclotron and external beam-line

EJNMMI Physics
Background Zirconium-89 (89Zr) is a highly valued diagnostic radionuclide for positron emission tomography (PET) due to its long physical half-life of 78.4 h and decay characteristics, being preferred for the radiolabelling of nanoparticles and slow ...
Diana Cocioabă, Simona Baruta, Liviu Crăciun, Radu Leonte, Andrei Necsoiu, Maria-Roxana Tudoroiu-Cornoiu, Alexandru Jipa, Dana Niculae   +7 more
doaj   +1 more source

Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands

EJNMMI Radiopharmacy and Chemistry
Background Programmed cell death ligand 1 (PD-L1) plays a critical role in the tumor microenvironment and overexpression in several solid cancers has been reported. This was associated with a downregulation of the local immune response, specifically of T-
Fabian Krutzek, Cornelius K. Donat, Sven Stadlbauer   +2 more
doaj   +1 more source

In Vitro Characterization of the Published Glypican-3-Targeting Peptide TJ12P2 Reveals a Lack of Specificity and Potency

Pharmaceuticals
Background/Objectives: The cell surface proteoglycan glypican-3 (GPC3) is reportedly overexpressed in hepatocellular carcinoma (HCC) tissues, but not in benign liver tissues, rendering this protein a potential target for radionuclide theranostic ...
Eva-Maria Burger, Charlice Hill, Robert Wodtke, Kristof Zarschler, Markus Laube, Cornelius K. Donat, Sandra Hauser, Klaus Kopka, Jens Pietzsch, Sven Stadlbauer   +9 more
doaj   +1 more source

Terbium-149 production: a focus on yield and quality improvement towards preclinical application

Scientific Reports
Terbium-149 (T1/2 = 4.1 h, Eα = 3.98 MeV (16.7%), 28 µm range in tissue) is a radionuclide with potential for targeted alpha therapy. Due to the negligible emission of α-emitting daughter nuclides, toxicity to healthy tissue may be reduced in comparison ...
C. Favaretto, P. V. Grundler, Z. Talip, U. Köster, K. Johnston, S. D. Busslinger, P. Sprung, C. C. Hillhouse, R. Eichler, R. Schibli, C. Müller, N. P. van der Meulen   +11 more
doaj   +1 more source

Toward Personalized Immunotherapeutic Drug Monitoring with Multiplexed Extended‐Gate Field‐Effect‐Transistor Biosensors

Small Science
The selection and optimization of therapies for cancer patients urgently need personalization. Portable point‐of‐care electronic biosensors emerge as a groundbreaking solution contributing to better decision‐making in precision oncology.
Trang‐Anh Nguyen‐Le, Christin Neuber, Isli Cela, Željko Janićijević, Liliana Rodrigues Loureiro, Lydia Hoffmann, Anja Feldmann, Michael Bachmann, Larysa Baraban   +8 more
doaj   +1 more source

Repurposing radiopharmaceutical carriers for targeted drug delivery and theranostics: A translational framework. [PDF]

Pharm Sci Adv
Shahiwala AF.
europepmc   +1 more source